Israel-based MigVax Corp, a company developing its MigVax-101 vaccine for COVID-19, announced on Tuesday that it has named Dr Eyal Desheh as the chairman of its board of directors.
Dr Desheh has been serving as chairman of the board of directors of Isracard Group. He has also been the executive vice president and chief financial officer of Teva Pharmaceuticals and executive vice president and chief financial officer of Check Point Software Technologies.
Dr Desheh said said, 'I am very happy to join this global effort to defeat the COVID-19 pandemic which has devastated our world by creating a severe health and economic crisis. An amazing and talented team of scientists in the north of Israel created a promising infrastructure for the development of vaccines for COVID-19 and its' like. At MigVax we are working as hard and as fast as we can to make this a reality.'
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business